Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine...

Area of Science:

• Anesthesiology
• Pharmacology
• Neuromuscular blockade

Background:

• Succinylcholine administration frequently causes muscle fasciculations and myalgia.
• Rocuronium is a neuromuscular blocking agent used to mitigate these adverse effects.
• Optimizing rocuronium dosage is crucial for balancing efficacy and safety.

Purpose of the Study:

• To determine the optimal dose of rocuronium for preventing succinylcholine-induced fasciculations and myalgia.
• To assess the impact of varying rocuronium precurarization doses on succinylcholine's onset of action.

Main Methods:

• A randomized, double-blind study involving 100 patients.
• Five groups received different rocuronium precurarization doses (0.02–0.06 mg/kg).
• Neuromuscular blockade was monitored using acceleromyography; fasciculations and myalgia were assessed.

Main Results:

• Increasing rocuronium doses significantly reduced the incidence and severity of muscle fasciculations (P < 0.001).
• Myalgia incidence showed a decreasing trend with higher rocuronium doses, though not statistically significant (P = 0.072).
• The onset time of succinylcholine was significantly prolonged with increasing rocuronium doses (P < 0.001).

Conclusions:

• Precurarization with 0.04 mg/kg rocuronium is identified as the optimal dose.
• This dose effectively reduces fasciculation and myalgia incidence and severity.
• The 0.04 mg/kg dose offers a safe and effective precurarization strategy with acceptable succinylcholine onset time.